Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab

被引:35
作者
Barrios, Carlos Henrique [1 ]
Reinert, Tomas [1 ]
Werutsky, Gustavo [1 ]
机构
[1] Latin Amer Cooperat Oncol Grp, 99,Av Ipiranga 6681, BR-90619 Porto Alegre, RS, Brazil
关键词
breast neoplasm; HER2; trastuzumab; drug therapy; REAL-WORLD; BIOSIMILARS; SURVIVAL; CARE; DISPARITIES; THERAPY; MORTALITY; COUNTRIES; MIDDLE;
D O I
10.3332/ecancer.2019.898
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Provision of high-level healthcare is a challenge for all low-to middle-income countries (LMICs) since healthcare systems are heterogeneous, face many challenges such as inadequate funding, inequitable distribution of resources and services and usually are not adequately equipped to deal with a huge problem such as breast cancer. The development of anti-HER2 therapies can be considered one of the most important examples of the translation of molecular biology knowledge into clinical benefits for cancer patients. While a variety of novel therapeutic strategies are emerging, current treatment regimens remain focussed on targeted therapy with monoclonal antibodies, mainly trastuzumab, the first agent developed in this field. While these results have revolutionised the outcome of HER2+ patients in clinical trials and in high-income countries where they are widely available, results have not impacted the natural history of this aggressive disease in most of the world. Unfortunately, the availability of these drugs is far from universal in many LMICs, and in Latin America, in particular, patients with HER2+ breast cancer are treated exclusively with standard chemotherapy, a more toxic and less efficient therapy. While the complexity of the situation and the multiple factors that have an impact in this scenario are recognised, we need to map the future and develop feasible strategies to address possible solutions to the problem of drug access. A clear and unbiased diagnosis of the situation is a good starting point. Defining healthcare priorities and a clear strategy for the allocation of resources is difficult but mandatory. In this article, we will discuss current and future challenges regarding access (and lack of access) to high-cost cancer drugs in Latin America, with a focus on anti-HER2 therapies.
引用
收藏
页数:12
相关论文
共 48 条
[1]   Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states [J].
Ades, F. ;
Senterre, C. ;
de Azambuja, E. ;
Sullivan, R. ;
Popescu, R. ;
Parent, F. ;
Piccart, M. .
ANNALS OF ONCOLOGY, 2013, 24 (11) :2897-2902
[2]   Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA [J].
Ades, Felipe ;
Senterre, Christelle ;
Zardavas, Dimitrios ;
de Azambuja, Evandro ;
Popescu, Razvan ;
Piccart, Martine .
PLOS ONE, 2017, 12 (03)
[3]  
[Anonymous], MED ACESS POINT CARE
[4]  
[Anonymous], J CLIN ONCOL
[5]  
[Anonymous], BRAZ J ONCOL
[6]   An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia [J].
Antonio Buendia, Jefferson ;
Vallejos, Carlos ;
Pichon-Riviere, Andres .
BIOMEDICA, 2013, 33 (03) :411-417
[7]  
Barrios Carlos H, 2018, Am Soc Clin Oncol Educ Book, V38, P441, DOI 10.1200/EDBK_209183
[8]   Approval of the first biosimilar antibodies in Europe A major landmark for the biopharmaceutical industry [J].
Beck, Alain ;
Reichert, Janice M. .
MABS, 2013, 5 (05) :621-623
[9]   The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer [J].
Blackwell, Kimberly ;
Gligorov, Joseph ;
Jacobs, Ira ;
Twelves, Chris .
CLINICAL BREAST CANCER, 2018, 18 (02) :95-113
[10]  
Cazap Eduardo, 2018, Am Soc Clin Oncol Educ Book, V38, P451, DOI 10.1200/EDBK_201315